SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Chip

Chip is experiencing high volatility following its simultaneous listing on major trading platforms, sparking a fierce debate within the community regarding its long-term potential as an AI infrastructure token versus its risk as a potential pump-and-dump scheme. Investors are actively discussing the token's circulating supply, its connection to GPU-backed lending, and the aggressive short-selling activity that has emerged alongside its recent price swings.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic remains a subject of intense community debate, with proponents pointing to consistent monthly token burns by Binance and ecosystem developments like the LUNCVERSE as catalysts for a potential long-term recovery. Meanwhile, skeptics continue to label the asset a failed project, highlighting ongoing volatility and lingering sentiment from the original ecosystem collapse as key reasons for caution.

Airgain, Inc. provides embedded antenna products, integration support and test services. The firm works in partnership with the entire ecosystem, including carriers, chipset suppliers, OEMs, and ODMs. Its products include embedded, external and carrier-class antennas. The company offers custom antenna design and performance validation services. Its antennas are deployed in carrier, fleet, enterprise, residential, private, government, and public safety wireless networks and systems, including set-top boxes, access points, routers, modems, gateways, media adapters, and asset tracking devices. The company was founded on March 20,1995 and is headquartered in San Diego, CA.

Airgain Inc

Airgain Inc is trending following news of a multi-million dollar design win with a major U.S. utility to deploy its wireless connectivity technology across its fleet. Investors are actively discussing the potential impact of this contract and whether the company can maintain this momentum to drive long-term revenue growth.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is trending as traders discuss a potential short squeeze and high-volume price surge, with many speculating on the impact of upcoming governance proposals and Solana ecosystem growth. Community sentiment remains divided between those aggressively accumulating the asset for its perceived low-float upside and skeptics who are monitoring for signs of profit-taking or volatility.

FLOKI is a community-driven, multi-chain utility token that powers a broad ecosystem including decentralized gaming, finance, and educational platforms. Originally evolving from a meme-based asset, the project now focuses on a utility-driven model centered around three pillars: community engagement, technical utility, and global charity work, balancing this ecosystem growth with social impact, such as building schools in developing nations like Ghana and Nigeria.  Key features include Valhalla, an NFT metaverse game where the token serves as the primary currency for capturing creatures and upgrading characters. The ecosystem also features the FlokiFi Locker for securing digital assets and the University of FLOKI for web3 education,with real-world integration facilitated through a prepaid debit card for everyday purchases at global stores. Staking FLOKI allows users to earn rewards in a sister token.  The project is led by a group of core advisors known by pseudonyms such as Sabre and B (The Viking) and is officially backed by DWF Labs, a major digital asset investment firm and market maker. While a small tax on decentralized trades helps fund development, value moves through the system as users utilize the token to pay for in-game items, access asset-locking services, or purchase merchandise.

Floki Token

Floki is currently generating significant community buzz as investors focus on its expansion into institutional finance through ETP listings and ongoing ecosystem developments like the Valhalla metaverse. Supporters are actively discussing the token's potential for a broader meme sector rally, often highlighting its historical trend patterns and anticipation of future liquidity cycles.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently sparking intense debate within the community, with many investors actively accumulating during the current price consolidation while others express frustration over the lack of major project milestones and price momentum. Sentiment remains deeply polarized between those maintaining long-term conviction in the project's utility and those concerned by the significant lag in performance compared to broader market trends.

Silicon Motion Technology Corp. engages in the development, manufacture, and supply of semiconductor products for the electronics market. Its products include Flash Controllers, Storage Solutions, and others. It offers embedded and expandable storage, radio frequency integrated circuits and embedded graphics. The company was founded in November 1995 and is headquartered in Hong Kong.

Silicon Motion Technology Corp - ADR

Silicon Motion Technology Corp.

Silicon Motion is seeing significant volatility and investor interest following news that Chinese regulators have conditionally cleared its long-standing merger deal with MaxLinear. The community is actively debating the implications of the acquisition's path forward, with traders closely monitoring the spread between the current price and the deal's implied value as they navigate heightened volume and regulatory uncertainty.

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

Lantheus Holdings Inc

Lantheus Holdings is trending as investors monitor its ongoing strategic investment in Radiopharm Theranostics, fueling speculation about potential M&A activity given the company's aggressive expansion in the radiopharmaceutical space. The community is actively discussing the long-term growth potential of its diagnostic pipeline and closely analyzing management's ability to navigate increased competition in key imaging markets.

Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The firm operates through the Software and Services segment. The Software segment offers software products for pharmaceutical research, development, and commercialization of the firm's products. The Services segment focuses on contracted consulting studies for customers and offers services supporting marketplace insight and medical communications for clinical and commercial drug development. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Durham, NC.

Simulations Plus Inc.

Simulations Plus Inc. is trending following an earnings report that triggered notable price movement and sparked debate among market participants about the company's growth trajectory, valuation, and competitive positioning in the AI-driven drug development sector. The community is actively discussing the stock's recent volatility, the impact of lowered guidance, and whether the company's specialized biosimulation software remains a strong long-term value proposition.

KAT is a defi token with governance-like mechanics for Katana.  It is designed to function as a lever for directing capital: users that lock KAT receive a voting version of KAT — vKAT — in return. vKAT underpins key aspects of the chain’s economy, providing rewards to those users that participate. these fee-based rewards function as an incentive for KAT holders to engage in cooperative, positive-sum behavior.

Katana

Katana is gaining significant attention following the adoption of a new ve-style tokenomics system aimed at enhancing DeFi liquidity and accrual across the network. Community sentiment remains polarized as participants monitor recent volatility and technical consolidation while weighing the potential impact of future ecosystem developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

A Few Reasons Why Small-Cap ETFs Are Good Bets Now

Small-cap ETFs show resilience amid war jitters, backed by domestic focus, lower energy risks for the United States, a steady Fed and earnings strength.

ETF Winners & Losers of Q1 2026

Iran war reshaped Q1 markets: energy, shipping & lithium ETFs surged while tech and airlines lagged as inflation fears and oil shocks rattled sentiment.



<ul class="summary-bullets"><li>UniQure’s AMT-130 is a gene therapy to reduce levels of the Huntingtin protein in the brain.</li><li>The FDA recently said that data from uniQure’s Phase I/II trials were not sufficient and recommended a new randomized Phase III study.</li><li>RBC Capital estimates a 50% chance of eventual approval as Prasad’s exit could reopen a more balanced discussion at the FDA about the risk-benefit profile of AMT-130.</li></ul>Shares of uniQure N.V. (QURE) surged more than 20% on Monday, following upgrades from Wall Street firms, citing a potentially improving regulatory outlook for its Huntington’s disease therapy.Wells Fargo upgraded the company to ‘Overweight’ from ‘Equal Weight’ and sharply raised its price target to $60 from $15, according to The Fly. This implies a 243% potential rise from its current price of around $17.5.<h2 class="st-heading-2">Vinay Prasad’s Reported Departure In Spotlight</h2>Wells Fargo said the outlook for uniQure’s experimental gene therapy AMT-130 could improve following reports that Vinay Prasad will leave the U.S. Food and Drug Administration (FDA) next month. Prasad, who serves as both the Chief Medical and Scientific Officer and the Director of the Center for Biologics Evaluation and Research at the FDA, is set to leave next month, according to a Bloomberg report on Friday.Wells Fargo also noted that strong criticism from the media and the Huntington’s disease community over the FDA’s call for a new Phase 3 trial highlights stakeholder support for the therapy. That backing could strengthen the drug’s chances during review, approval, and commercialization.AMT-130 is a gene therapy to reduce levels of the Huntingtin protein in the brain. It uses a virus to deliver genetic instructions that help lower the protein. The treatment is administered directly into the striatum, an area of the brain heavily affected by Huntington’s disease, through a surgical procedure.Separately, RBC Capital Markets upgraded uniQure to ‘Outperform’ from ‘Sector Perform’ and raised its price target to $35 from $11. The firm said Prasad’s exit could reopen a more balanced discussion at the FDA about the risk-benefit profile of AMT-130, estimating about a 50% chance of eventual approval.<h2 class="st-heading-2">FDA Seeks New Randomized Study</h2>The upgrades come after regulatory uncertainty weighed on the company earlier this year. The FDA recently said that data from uniQure’s Phase I/II trials were insufficient to support a marketing application and recommended that the company conduct a new randomized Phase III study, including a controversial sham surgery control group.uniQure has raised ethical concerns about such a trial design, arguing that it could expose patients to surgical risks without therapeutic benefit. The company plans to request another meeting with the FDA in the second quarter of 2026 to discuss potential study designs.Despite the regulatory debate, AMT-130 has shown promising early data. In an earlier study, patients receiving a high dose of the gene therapy experienced about a 75% slower rate of disease progression after three years, along with a slower decline in both motor function and cognitive ability.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp rally, retail sentiment for <a href="https://stocktwits.com/symbol/QURE">QURE</a> on Stocktwits turned ‘bullish’ from ‘extremely bullish’ a day earlier, amid ‘extremely high’ message volumes.One user expects the stock to surge to $150 if the company receives the FDA approval.<stembedurl>https://stocktwits.com/ChineseTakeeout/message/646975511</stembedurl>Another user weighed the options present for short sellers and long-term investors.<stembedurl>https://stocktwits.com/sepsis74/message/646972082</stembedurl>The stock has declined nearly 28% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/saudi-arabia-begins-slashing-oil-production-tpet-batl-indo-shares-continue-to-draw-retail-buzz/cZdVlsWRIIj">Saudi Arabia Begins Slashing Oil Production – TPET, BATL, INDO Stocks Continue To Draw Retail Buzz</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150

Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month.

Equity

<ul class="summary-bullets"><li>Aardvark voluntarily paused the HERO Phase 3 trial on Friday after a routine safety monitoring of a healthy volunteer found reversible cardiac effects.</li><li>Aardvark said it no longer expects to release HERO trial topline data in Q3 2026.</li><li>Stifel called the development a “surprise” and said that the “added uncertainty is hard to get comfortable with.”</li></ul>Shares of Aardvark Therapeutics (AARD) plummeted 4% in pre-market trading on Monday after a wave of bearish analyst downgrades following the company’s decision to pause its Phase 3 trial evaluating the treatment for hyperphagia in patients with Prader-Willi syndrome.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/AARD">AARD shares</a> could fall to their lowest levels since Apr. 9, 2025.On Friday, Aardvark said it voluntarily paused the HERO Phase 3 and related extension trials after a routine safety monitoring of a healthy volunteer found reversible cardiac effects at doses above the target therapeutic level.Aardvark said it no longer expects to release HERO trial topline data in the third quarter (Q3) of 2026 and will instead provide updated guidance in the second quarter.<h2 class="st-heading-2">Analyst Expresses Skepticism About The New Uncertainty</h2>Stifel downgraded Aardvark Therapeutics to ‘Hold’ from ‘Buy’ and reduced its price target to $6 from $24, according to The Fly. This represents a 52% downside to Friday’s closing price of $12.5. The brokerage called the development a “surprise” and said that the “added uncertainty is hard to get comfortable with.” It is “very hard to build confidence in what the path forward may look like,” Stifel added.Morgan Stanley downgraded Aardvark Therapeutics to ‘Equal Weight’ from ‘Overweight’ and significantly slashed its price target to $7 from $29, according to The Fly. While the brokerage still sees potential for ARD-101, it lowered its rating due to near-term uncertainties.RBC Capital said that timelines are likely to be significantly delayed as the Aardvark works with the FDA on next steps, adding a “layer of uncertainty” around the program. The brokerage downgraded the stock to ‘Sector Perform’ from ‘Outperform’ and cut its price target to $6 from $18.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>While retail sentiment on Stocktwits remained ‘extremely bullish,’ amid ‘extremely high’ message volumes, chatter was largely ‘bearish’.<img src="https://news.stocktwits-cdn.com/AARD_jpg_eaa4fec962.webp" alt="AARD.jpg">One user said the suspension of the trial was “one of the worst news.”<stembedurl>https://stocktwits.com/focafoca99/message/646219667</stembedurl>Another user expects the stock to decline to $3.<stembedurl>https://stocktwits.com/jojoraizza/message/646210388</stembedurl>The stock has lost around 56% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/spy-falls-100-day-moving-average-oil-vix-middle-east-tensions/cZd33g2RIcH">SPY On Track To Fall Below 100-DMA For First Time In Nine Months – Retail Braces For Prolonged Volatility</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial

Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did NGNE Stock Surge 25% In Pre-Market Today?

The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome.

This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target 

<ul class="summary-bullets"><li>Vanda noted that in the Gemini-1 and Gemini-2 studies evaluating the efficacy of Imsidolimab, more than half of the patients achieved clear or almost clear skin by the fourth week, compared to 13% on placebo.</li><li>The company said that efficacy was maintained throughout an approximately 2-year maintenance period with monthly doses, and no flares occurred in the active treatment arm.</li><li>Vanda added that GPP is a rare disorder with prevalence estimates varying widely by region, ranging from approximately 2 to 124 cases per million worldwide.</li></ul>Vanda Pharmaceuticals Inc. (VNDA) on Wednesday announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application for Imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP).The company noted that if the FDA approves its application, Imsidolimab could address a significant unmet medical need in this rare and life-threatening disorder.<a href="https://stocktwits.com/symbol/VNDA">Vanda shares</a> were up nearly 5% in Wednesday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory at the time of writing.<h2 class="st-heading-2">Vanda Says Over Half Of Patients Achieved Clear Or Almost Clear Skin</h2>Vanda noted that in the Gemini-1 and Gemini-2 studies evaluating the efficacy of Imsidolimab, more than half of the patients achieved clear or almost clear skin by the fourth week, compared to 13% on placebo.The company said that efficacy was maintained throughout an approximately 2-year maintenance period with monthly doses, and no flares occurred in the active treatment arm.Vanda added that GPP is a rare disorder with prevalence estimates varying widely by region, ranging from approximately 2 to 124 cases per million worldwide.“Imsidolimab builds on our growing expertise in rare orphan disorders and our anti-inflammatory portfolio. Imsidolimab represents a precision medicine approach targeting a disorder with a known genetic cause using a fully humanized monoclonal antibody against the IL-36 receptor,” said Vanda CEO Mihael H. Polymeropoulos.<h2 class="st-heading-2">What Does Vanda Do?</h2>Vanda Pharmaceuticals is a Washington-based biopharmaceutical company focused on the development and commercialization of therapies that cater to highly unmet medical needs.Imsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling. The company expects regulatory and patent exclusivity for the treatment to extend into the late 2030s.<a href="https://stocktwits.com/symbol/VNDA">VNDA stock</a> is down 7% year-to-date, but up 88% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rxrx-stock-soars-pre-market-on-q4-beat-recursion-reached-inflection-point/cZRy27nR46D">RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Vanda Pharmaceuticals Inc. logo is pictured before a regular season Major League Baseball game between the Chicago White Sox and the Detroit Tigers on September 05, 2025. (Photo by Joseph Weiser/Icon Sportswire via Getty Images)

Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder

Vanda Pharma company noted that if the FDA approves its application, Imosidolimab could address a significant unmet medical need in this rare and life-threatening disorder.

The company noted that if the FDA approves its application, Imosidolimab could address a significant unmet medical need in this rare and life-threatening disorder.

<ul class="summary-bullets"><li>H.C. Wainwright raised MoonLake’s price target to $32 from $26 and maintained a ‘Buy’ rating.</li><li>BTIG said the FDA approval ‘clears a significant overhang’ for MoonLake’s clinical program.</li><li>MoonLake plans to submit its biologics license application in the second half of 2026.</li></ul>MoonLake Immunotherapeutics (MLTX) remained on investors’ radar after its shares rose 5% in premarket trading on Friday, following favorable brokerage action tied to positive feedback from the U.S. Food and Drug Administration (FDA) on its treatment for hidradenitis suppurativa, a chronic inflammatory skin condition.<a href="https://stocktwits.com/symbol/MLTX">MLTX</a> was among the top trending tickers on Stocktwits at the time of writing.BTIG upgraded MoonLake Immunotherapeutics to ‘Buy’ from ‘Neutral’ and set a $24 price target, citing a recent regulatory update, according to TheFly.<h2 class="st-heading-2">The FDA Feedback</h2>The FDA <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mltx-stock-jump-45-in-pre-market-today/cmUbJFWR4Pt">confirmed</a> that MoonLake can establish the effectiveness of Sonelokimab (SLK) in hidradenitis suppurativa without additional trials, a development BTIG believes clears a significant overhang for the company’s clinical program and could position SLK for FDA approval.This would be supported by existing data from the VELA-1, VELA-2, and MIRA studies. The company plans to submit its biologics license application in the second half of 2026.H.C. Wainwright raised MoonLake’s price target to $32 from $26 and maintained a ‘Buy’ rating. The company’s FDA meeting outcome delineates a path to registration, the firm said.The stock closed 27% higher on Thursday following the FDA feedback.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/MLTX_jpg_6f56883898.webp" alt="MLTX.jpg">One user sees potential conversations regarding mergers and acquisitions following the FDA feedback.<stembedurl>https://stocktwits.com/Atdanaiw/message/641311151</stembedurl>Another user believes MLTX’s value needs to grow further before a probable acquisition.<stembedurl>https://stocktwits.com/Newcar/message/641308484</stembedurl>MoonLake had reportedly turned down a $3 billion acquisition offer from Merck (MRK) in June last year.The stock has been under heavy selling pressure over the past year, declining more than 70%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/glue-stock-slips-pre-market-after-pricing-300-million-public-offer-at-discount/cmU2ghYR4dQ">GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations

BTIG upgraded MoonLake Immunotherapeutics to ‘Buy’ from ‘Neutral’ after the FDA said the company could show the effectiveness of Sonelokimab without additional HS trials.

<ul class="summary-bullets"><li>The FDA feedback indicates the company can establish&nbsp;substantial evidence of effectiveness without conducting additional&nbsp;hidradenitis suppurativa trials.</li><li>The firm remains on track to submit its Biologic License Application for Sonelokimab in the second half of 2026.</li><li>MoonLake will host an Investor Day on February 23 to review FDA feedback from the Type B meeting.</li></ul>Shares of MoonLake Immunotherapeutics (MLTX) surged 45% in premarket trading on Thursday after the company said it received positive regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Type B meeting regarding Sonelokimab (SLK), a drug used to treat hidradenitis suppurativa (HS), a chronic inflammatory skin disorder.The FDA feedback indicates the company can establish substantial evidence of effectiveness (SEE) without conducting additional HS trials, using a Biologic License Application (BLA) supported by data from its existing VELA-1, VELA-2, and MIRA studies.The agency advised including MIRA results to support efficacy and submitting VELA-2 data to inform the safety profile. Based on the official meeting outcome, the company remains on track to submit its BLA for Sonelokimab in the second half of 2026.“The positive outcome of our Type B meeting with the FDA provides the clarity needed to support a pathway to approval for our existing HS program, with no additional clinical trials required. In addition, the fact that we can prepare the BLA with the wealth of data across the VELA and MIRA trials provides us and the FDA with flexibility to determine the best label possible, so that SLK, if approved, can have the most positive impact for HS patients,” said Jorge Santos da Silva, Founder and Chief Executive Officer at MoonLake Immunotherapeutics.<h2 class="st-heading-2">2026 Pipeline</h2>MoonLake will host an Investor Day on Feb. 23, 2026, to review the FDA feedback from the Type B meeting and share new clinical data for SLK across indications, along with updates to its 2026 catalyst outlook.The company also expects a steady flow of clinical readouts over the next year, including Phase 2 data in axial spondyloarthritis and multiple Phase 3 updates in psoriatic arthritis and HS. Key milestones include a Phase 2 axSpA readout in Q1 2026, several Phase 3 readouts by mid-2026, and a planned BLA submission in the second half of 2026.<h2 class="st-heading-2">How Did Stockwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high’ message volumes. <a href="https://stocktwits.com/symbol/MLTX">MLTX</a> was among the top trending stocks on the platform at the time of writing.<figure class="image"><img src="https://news.stocktwits-cdn.com/MLTX_jpg_70c33bd6fe.webp" alt="MLTX.jpg" width="916" height="96"><figcaption>MLTX's Sentiment Meter and Message Volumes at Premarket on Jan. 8, 2026 | Source: Stocktwits</figcaption></figure>One user expects the stock to climb to $22 within a few sessions. It is currently trading at $16.2.<stembedurl>https://stocktwits.com/discountcroesus1/message/641193716</stembedurl>The stock has been under heavy selling pressure over the past year, declining nearly 80%.Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/why-vnda-stock-falling-premarket/cmUbEA9R4Pn">Vanda Stock Drops 10% Premarket After FDA Rejects Jet Lag Drug Application</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Did MLTX Stock Jump 45% In Pre-Market Today?

The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder.

Can ETF Winners of Q4 of 2025 Rally in Q1 of 2026?

Q4's top ETF winners -- silver, biotech and lithium -- outpaced markets. Can SIVR, SLV, BBC and LITP extend gains into 2026?

<ul class="summary-bullets"><li>H.C. Wainwright conservatively expects approval by the middle of 2026 and sees the shares trading well into the year-end.</li><li>Capricor’s bumper rally on Wednesday helped the stock turn green for the year.</li><li>Retail sees the stock as a long-term winner following the Phase 3 results.</li></ul>Two decades after its modest beginnings and more than a decade after becoming a public company, San Diego, California-based Capricor Therapeutics made another stride toward becoming a commercial-stage company. After a failed first try, the small-cap biotech is hoping to push its experimental cell-therapy for a rare genetic muscular disorder past the finish line without any hiccups.Wall Street analysts and the investment community received the recently released late-stage trial data for the treatment candidate well. While sell-side analysts were generous with their price target hikes, signaling their excitement toward the data, investors sent the stock up by over 530% at one point in Wednesday’s session. The initial euphoria faded slightly, but didn’t die out, as<a href="https://stocktwits.com/symbol/CAPR">&nbsp;Capricor’s stock</a> had enough verve to finish the day up 371% at $29.96,&nbsp;ending at an eight-year high and marking its best day ever.<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_04_at_2_28_48_AM_png_599beb080a.webp" alt="Screenshot 2025-12-04 at 2.28.48 AM.png">Source: Koyfin<h2 class="st-heading-2">What Fueled CAPR’s Stratospheric Rally</h2>Wednesday, before the market opened, Capricor reported positive topline results from the Phase 3 study, dubbed HOPE-3, evaluating its Duchenne Muscular Dystrophy (DMD) cell therapy candidate, Deramiocel.-The primary endpoint, measured as the performance of upper limb (PUL), was met — showing statistically and clinically meaningful treatment effects in 54% of the patients.-The key secondary endpoint of “Left Ventricular Ejection Fraction (LVEF),” a measure of heart health, was also met.&nbsp;Thus, Deramiocel was shown to produce significant skeletal and cardiac benefits, supporting its credentials as a potential “first-in-class therapy” for Duchenne cardiomyopathy, the leading cause of mortality in DMD. The trial also gave the cell therapy a clean chit for its safety and tolerability.Capricor said it would submit the detailed results from the HOPE-3 study at a future scientific meeting and for publication in a peer-reviewed journal.Earlier in July, the FDA shot down Capricor’s initial application for Deramiocel, issuing a complete response letter (CRL) — a notice that an application cannot be approved in its current form. The agency expressed wariness about the company's efficacy data at the time and sought additional data. Industry experts saw it as a signal that the new leadership at the FDA could be veering toward a cautious approach.&nbsp;&nbsp;CEO Linda Marbán said the study results, in addition to the evidence from the HOPE-2 and HOPE-2 OLE studies, would address the clinical issues in the CRL and support regulatory approval.DMD is caused by a mutation in the DMD gene that prevents the body from producing the protein dystrophin. A lack of dystrophin hits muscle fibres, leading to muscle damage and loss.&nbsp;<h2 class="st-heading-2">What’s At Stake For Capricor</h2>According to Grand View Research, the DMD drugs<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.grandviewresearch.com/industry-analysis/duchenne-muscular-dystrophy-dmd-drugs-market">&nbsp;market</a> is expected to grow at a compounded annual growth rate (CAGR) of 16.8% from 2024, reaching $9.91 billion in 2030. North America’s revenue share was at 45% in 2023. Global Data, meanwhile, has a more muted forecast, predicting a $5.2 billion market opportunity in 2033.&nbsp;<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_04_at_3_25_08_AM_png_f4173223fa.webp" alt="Screenshot 2025-12-04 at 3.25.08 AM.png">Source: Grandview ResearchThe DMD market is currently led by Sarepta, which has a gene-replacement therapy called Eteplirsen. Elevidys, a one-time single-dose gene transfer therapy, was approved in June 2023, and its label was expanded a year later to include patients ages four and older. The gene therapy generated $131.5 million in revenue for Sarepta in the third quarter.Capricor’s Deramiocel differs from Elevidys in that it is a cell therapy that administers the patient's cardiosphere-derived cells, which secrete exosomes. The latter uses a manufactured gene for delivering the micro-dysrophin gene.Sarepta also has three FDA-approved exon-skipping therapies, Exondys 51, Amondys 45 and Vyondys 53, and it is also currently working on RNA therapies.<h2 class="st-heading-2">Big Price Target Bumps</h2>Following the data, H.C. Wainwright upped the price target for Capricor's stock to $60 from $24 and kept a 'Buy' rating, the Fly reported. The firm called the data a "decisive" win. With 78% of participants having underlying cardiomyopathy, the trial results addressed FDA concerns about sample size, the firm said. It conservatively expects approval by the middle of 2026 and sees the shares trading well into the year-end.Alliance Global called the data "unequivocally and wholly positive" and removed the speculative tag from the stock. The firm hiked its price target for the stock to $48 from $16.<h2 class="st-heading-2">Retail Convinced Of Capricor Opportunity</h2>On Stocktwits, retail investors held an 'extremely bullish' stance on Capricor stock as of early Thursday. The message volume on the stream was 'extremely high as well.A majority of retail traders are sold on Capricor's long-term potential. An ongoing Stocktwits poll asking users "What's your move on $CAPR after this Phase 3 win?" found that 53% of respondents said "This is legit — CAPR becomes a long-term winner," while 18% remained on the sidelines, waiting for approval to come through. About 29% shrugged off the rally as an "overreaction."<a href="https://stocktwits.com/StocktwitsPolls/message/638043423"><img src="https://news.stocktwits-cdn.com/CAPR_Stocktwits_poll_png_bc7624531b.webp" alt="CAPR Stocktwits poll.png"></a>CAPR stock has&nbsp;soared about 117% this year, as Wednesday's bumper rally helped it recoup all its losses to that point and turn green for the year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/core-weave-vs-nebius-ai-infra-s-breakout-duo-backed-by-nvidia-is-outrunning-big-tech/cLIXYiKRE12">&nbsp;</a><a href="https://stocktwits.com/news-articles/markets/equity/whispers-of-an-apple-deal-rebooted-intel-s-year/cLIXAvERE1L">Whispers Of An Apple Deal Rebooted Intel’s Year — Now The Market’s Asking Whether The Old Chip Giant Can Rise Again</a>

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Capricor’s Red-Hot Rally Has Wall Street And Retail Hooked — And Fresh DMD Data Could Keep Fueling The Fire

 DMD patients may soon gain access to a therapy that not only targets muscle decline but also tackles heart complications — the leading cause of death in this rare genetic disorder.

SBIO
ALPS Fund Services - ALPS Medical Breakthroughs ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest SBIO News

SBIOALPS Fund Services - ALPS Medical Breakthroughs ETF